Jingwei Yao

Xiamen, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Combination of HDAC inhibitor and PI3K inhibitor suppresses autophagy and induces apoptosis via cytoplasmic IκBα stabilization in p53-mutant diffuse large B-cell lymphoma.

Combination of HDAC inhibitor and PI3K inhibitor suppresses autophagy and induces apoptosis via cytoplasmic IκBα stabilization in p53-mutant diffuse large B-cell lymphoma.

Journal: Cell death discovery

Published: May 21, 2025

DGKα inhibition enhances the antitumor effect of chiauranib on transformed follicular lymphoma.

DGKα inhibition enhances the antitumor effect of chiauranib on transformed follicular lymphoma.

Journal: Annals of hematology

Published: March 18, 2025

Venetoclax confers synthetic lethality to chidamide in preclinical models with transformed follicular lymphoma.

Venetoclax confers synthetic lethality to chidamide in preclinical models with transformed follicular lymphoma.

Journal: Clinical epigenetics

Published: December 11, 2024

Chiglitazar diminishes the warburg effect through PPARγ/mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia.

Chiglitazar diminishes the warburg effect through PPARγ/mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia.

Journal: Experimental hematology & oncology

Published: September 03, 2024

Expression of interferon regulatory factor family and its prognostic value in acute myeloid leukemia.

Expression of interferon regulatory factor family and its prognostic value in acute myeloid leukemia.

Journal: Future oncology (London, England)

Published: December 06, 2023

Simvastatin Preferentially Targets FLT3/ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and p38-MAPK Signaling Pathways.

Simvastatin Preferentially Targets FLT3/ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and p38-MAPK Signaling Pathways.

Journal: Drugs in R&D

Published: September 18, 2023

Prognostic implications of cGAS and STING gene expression in acute myeloid leukemia.

Prognostic implications of cGAS and STING gene expression in acute myeloid leukemia.

Journal: Experimental biology and medicine (Maywood, N.J.)

Published: July 09, 2023

Ritanserin suppresses acute myeloid leukemia by inhibiting DGKα to downregulate phospholipase D and the Jak-Stat/MAPK pathway.

Ritanserin suppresses acute myeloid leukemia by inhibiting DGKα to downregulate phospholipase D and the Jak-Stat/MAPK pathway.

Journal: Discover oncology

Published: April 14, 2023

Anlotinib suppresses the DNA damage response by disrupting SETD1A and inducing p53-dependent apoptosis in Transformed Follicular Lymphoma.

Anlotinib suppresses the DNA damage response by disrupting SETD1A and inducing p53-dependent apoptosis in Transformed Follicular Lymphoma.

Journal: International journal of medical sciences

Published: April 04, 2023

CD4 T cells in chronic myeloid leukemia present MHC class II-dependent and IFN-γ-dependent cytotoxic capacity.

CD4 T cells in chronic myeloid leukemia present MHC class II-dependent and IFN-γ-dependent cytotoxic capacity.

Journal: Medical oncology (Northwood, London, England)

Published: March 24, 2023

Preclinical Studies of Chiauranib Show It Inhibits Transformed Follicular Lymphoma through the VEGFR2/ERK/STAT3 Signaling Pathway.

Preclinical Studies of Chiauranib Show It Inhibits Transformed Follicular Lymphoma through the VEGFR2/ERK/STAT3 Signaling Pathway.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: November 15, 2022

Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling.

Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling.

Journal: Journal of cancer research and clinical oncology

Published: September 21, 2022

Showing 1-12 of 13

Last Updated: 09/26/2026